The World Economic Forum (WEF) and the Harvard School of Public Health report entitled “The Global Economic Burden of Non-communicable Diseases” estimates global diseases kill 36 million people every year and will cost upwards of US$47 trillion by 2030.

 

The World Health Organization's four biggest killers; cancer, heart disease, diabetes and chronic respiratory disease are dominant in non-communicable disease (NCD) mortality and morbidity. All four are increasing in prevalence  and the cost of treatment is spiraling out of control.

 

Exactly what is Diabetes?

 

 

Diabetes is a condition in which blood sugar levels are too high.

 

Much of the food you eat is broken down into a simple sugar called glucose. In response to a rise in glucose levels after a meal the islets beta-cells in the pancreas read blood glucose  levels and secrete insulin into the blood. Insulin acts to open the gates of cells allowing the glucose to move from the blood stream into the cells where it can be utilized for energy.

 

A Type 1 diabetes diagnosis means the pancreatic beta cells that read glucose levels and secrete insulin have been damaged or destroyed. Thus glucose cannot move from the bloodstream into the cells.

 

A Type 2 (insulin resistance) diabetes diagnosis is a far more common verdict for people than Type 1. Insulin resistance happens because of chronically elevated blood sugar and insulin levels.

 

These elevated levels of sugar and insulin have the effect of "numbing" the cellular processes which move the sugar from the blood stream to the cells - the body cannot respond to the insulin "requests" to move blood sugar into the cells. Roughly 27% of the people who start out as Type 2 diabetics, will, in the future require insulin injections similar to Type 1 diabetics.

 

Between Type-1 and Type-2 patients with diabetes the total number of diabetics requiring insulin in just North America, is about nine million.

 

Sernova Corp. TSX:V-SVA is a Canadian-based medical device development company focused on chronic metabolic, neurological, and haematological diseases. Due to the enormous market and potential for significantly improved patient treatment, Sernova’s first product focus is on diabetes.

 

Sernova’s Cell Pouch System™ is a versatile, scalable credit card-sized device, made of FDA approved materials that provides a natural "organ-like" environment for therapeutic cells such as insulin producing islets for diabetics. Think of the Cell Pouch System™ as a potential natural insulin producing pump with the added benefit of fine-tuned glucose control. Placed under the skin in a simple inexpensive procedure it develops endocrine pancreas like characteristics when islets are placed into the device taking over normal glucose control. A key feature of the device is its ability to stimulate natural microvessel development, thought to be essential for long-term survival and function of therapeutic cells.

 

 

Latest News Release

Sernova Completes Oversubscribed Private Placement; Adds Management Depth with New CFO

Further to its news release of May 8, 2015, Sernova Corp. has completed a non-brokered private placement of 8,888,889 units at 18 cents per unit for gross proceeds of $1.6-million.

"We are pleased with the very strong interest from investors in Sernova's future in the regenerative medicine space as indicated by the oversubscription of the private placement," said Dr. Philip Toleikis, President and CEO of Sernova. Net proceeds from the private placement will be used to fund Sernova's regenerative medicine clinical program and collaborations utilizing the Company's platform technology to treat diabetes and other serious disease conditions, as well as for general corporate purposes.

Each Unit issued in the private placement consisted of one common share and one common share purchase warrant, with each warrant exercisable into one share at a price of $0.30 per share for a 24 month exercise period, subject to abridgement of the exercise period (after the expiry of the 4 month hold period) on 30 days notice to holders in the event that the twenty-day volume weighted price of the shares exceeds $0.50. Further, in respect of a portion of the private placement, the Company compensated finders by way of cash commissions of $26,451.18 and 137,151 non-transferable finder warrants, each such finder warrant having the same terms as the Unit warrants.

All securities issued in connection with the private placement will be subject to a statutory hold period of four months. This news release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act of 1933 or any state securities laws, and may not be offered or sold in the United States without registration under the U.S. Securities Act of 1933 and all applicable state securities laws, or an applicable exemption from registration requirements.

Appointment of CFO

Sernova is also pleased to announce that Ralph Deiterding, CPA, CA, CMA has joined the Company as its Chief Financial Officer. Mr. Deiterding is a finance veteran with over 20 years of experience, primarily in senior finance roles at Toronto Stock Exchange listed software vendors. Prior to joining Sernova, Mr. Deiterding was Director of Finance & Accounting at Lexington Park Real Estate Capital Inc., a real estate asset management firm. Previously, he held the positions of Corporate Controller for MKS Inc. and Controller at Workbrain Corporation, both software vendors listed on the Toronto Stock Exchange. While at Workbrain, he was an instrumental member of the team that completed the company's C$40 million Initial Public Offering. While at MKS, he was highly involved in the transition when the company was acquired by Parametric Technology Corporation, a NASDAQ listed software vendor, for C$292 million.

"We are delighted to have Mr. Deiterding on board as Sernova's CFO," stated Dr. Philip Toleikis, President and CEO of Sernova. "Given his expertise with Toronto Stock Exchange listed companies as well as his extensive experience with successful public market transactions, we are confident that he will make a great contribution to Sernova."

Sernova wishes to thank Mr. David Garland, the outgoing interim CFO, for his outstanding service to the Company.

 

Legal Notice / Disclaimer

 

This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment.

 

Richard Mills has based this document on information obtained from sources he believes to be reliable but which has not been independently verified.

 

Richard Mills makes no guarantee, representation or warranty and accepts no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of Richard Mills only and are subject to change without notice. Richard Mills assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission.

 

Furthermore, I, Richard Mills, assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information provided within this Report.


To contact us please email rick@aheadoftheherd.com

Ahead of the Herd
www.aheadoftheherd.com